Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

South Korea · Delayed Price · Currency is KRW

5,130.00

-100.00 (-1.91%)

Oct 23, 2026, 3:30 PM KST

Kyongbo Pharmaceutical Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	279,552	264,104	238,556	216,357	196,265	170,660
Revenue Growth	14.83%	10.71%	10.26%	10.24%	15.00%	-20.73%
Gross Profit	107,473	102,304	89,274	62,576	43,867	34,731
Operating Income	2,633	3,519	10,454	5,545	1,393	-6,625
Net Income	5,045	182.29	4,639	2,974	610.59	-7,495
Earnings Per Share	211.21	7.63	194.00	124.42	26.00	-314.00
EPS Growth	1123.64%	-96.07%	55.93%	378.52%	-	-

Revenue by Segment

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Raw Material	138,268	139,990	144,076	125,164	167,154
Finished Products	100,289	76,368	52,189	45,495	48,131

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	13,828	8,048	6,128	5,347	7,218	4,290
Total Debt	158,001	126,671	91,433	75,936	64,512	56,587
Net Cash (Debt)	-144,173	-118,623	-85,305	-70,589	-57,294	-52,296
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-6035.76	-4961.88	-3567.15	-2952.68	-2439.66	-2190.88

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	11,953	7,456	149.12	4,844	10,127	17,968
Capital Expenditures	-55,933	-41,538	-12,697	-9,693	-12,874	-17,506
Free Cash Flow	-43,980	-34,083	-12,547	-4,849	-2,747	461.73
Free Cash Flow Growth	-	-	-	-	-	-94.72%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	38.45%	38.74%	37.42%	28.92%	22.35%	20.35%
Operating Margin	0.94%	1.33%	4.38%	2.56%	0.71%	-3.88%
Pretax Margin	2.14%	0.17%	2.06%	1.00%	-0.31%	-5.82%
Profit Margin	1.80%	0.07%	1.94%	1.38%	0.31%	-4.39%
FCF Margin	-15.73%	-12.90%	-5.26%	-2.24%	-1.40%	0.27%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	24.29	756.70	32.05	67.44	391.54	-
P/FCF Ratio	-	-	-	-	-	556.60
PS Ratio	0.44	0.52	0.62	0.93	1.22	1.51